Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs

Capece, Daria; Iansante, Valeria; Fischietti, Mariafausta; Verzella, Daniela; Fargnoli, Maria Concetta; Peris, Ketty; Giacomelli, Roberto; Zazzeroni, Francesca; Alesse, Edoardo

doi:10.5772/26413

Cited by 1 publication

(1 citation statement)

References 109 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some approaches for increasing the number of effector T cells at the tumor site are based on the delivery of mAbs to activate surface costimulatory T cell receptors, such as B7, 4-1BB or OX40, which promote the expansion and increase the antitumor immune response of CD8 + T cells (Table 9). [329,330] In one report, the treatment of mice bearing B16F10 melanoma tumors with PEGylated liposomes decorated with the Ab 4-1BB (also known as CD137) and the same liposomes with an engineered fusion protein of IL-2 and a fragment crystallizable region of an antibody (IL-2Fc) anchored, led to a positive antitumor efficacy, with decreased systemic toxicity in comparison to the free drugs. [331] In another case, the same melanoma murine model was used to test the efficacy of PLGA NPs conjugated to anti-PD-1 and OX40 mAbs.…”

Section: Mabs To Induce the Antitumor Activity Of Immune Cellsmentioning

confidence: 99%

Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues

Dacoba

Anthiya

Berrecoso

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Research efforts towards cancer therapeutics have resulted in the development of a variety of pharmacological molecules, including small synthetic molecules and biological drugs (RNA-based therapies and monoclonal antibodies-mAbs), intended to target tumor or immune-related cells, or their signaling mediators. The majority of them present important biopharmaceutical problems related to their difficulties for overcoming biological barriers and reach their targets. Nanotechnology has been, for more than 60 years, trying to solve these problems. As knowledge in drug discovery, molecular biology, and biomaterials advances, there has been significant progress in the adequate design of nanodelivery strategies that may significantly contribute to the exploitation of the new therapies. This review provides a critical overview of the current potential of nanotechnology to solve problems associated with the different categories of drugs. Starting with the general concept of passive and active targeting, it presents the distinct advantages that delivery technologies have shown to date for improving the therapeutic outcome of small drugs with cytotoxic activity, RNA-and mAb-based therapies. Moreover, it precisely describes the benefits of combining immunotherapies and nanotechnology. The most advanced technologies are put into perspective in relation to their translational pathway and the future avenues for nano-oncologicals.

show abstract

Section: Mabs To Induce the Antitumor Activity Of Immune Cellsmentioning

confidence: 99%